Exosome therapy is one of the fastest-growing offerings in aesthetic and orthopedic clinics: injected into scalps for hair loss, layered onto microneedled skin, injected into knees and shoulders, infused intravenously for vague promises of "anti-aging" or immune support. It is often positioned as the next generation beyond PRP or stem cells.

The underlying science is genuinely interesting. The commercial products being sold are a different question, and the U.S. Food and Drug Administration has been unusually direct about it.

What exosomes actually are

Exosomes are tiny membrane-bound sacs — roughly 30 to 150 nanometers across — that cells release into their surroundings. They are one type of what researchers call extracellular vesicles. They carry proteins, lipids, and genetic material such as messenger RNA and microRNA, and they appear to be a way cells signal to one another.

That cargo is why researchers are interested. If a stem cell's benefit comes largely from the signals it sends rather than the cell itself, then in principle you could deliver the signals without the cell. Exosomes are also being studied as drug-delivery vehicles and as diagnostic biomarkers in cancer. A widely cited 2020 review in Science lays out the biology and the range of proposed biomedical applications (Kalluri and LeBleu, Science, 2020).

None of that is the same as evidence that a vial sold to a clinic does what the brochure says.

There are no FDA-approved exosome products

This is the single most important fact in this guide, and it is not a technicality.

The FDA states plainly that there are no FDA-approved exosome products, and that products claiming to contain exosomes for the treatment of disease or conditions are regulated as drugs and biological products — meaning they require an approved biologics license application, or at minimum an active investigational new drug application, before they can be marketed (FDA Public Safety Notification on Exosome Products).

Sellers sometimes argue that exosome products fall under the lighter-touch pathway for human cells, tissues, and cellular and tissue-based products — the "361 HCT/P" route in 21 CFR Part 1271, which allows certain minimally manipulated tissues used for the same basic function they served in the donor to be distributed without premarket approval. The FDA's position is that exosome products generally do not qualify. They are processed well beyond minimal manipulation, and injecting umbilical-cord- or placenta-derived vesicles into a scalp or a joint is not "homologous use."

What "not FDA-approved" does and doesn't mean

It does not mean the FDA has reviewed exosome therapy and rejected it. No agency has concluded it doesn't work.

It does mean that no manufacturer has completed the trials required to demonstrate that a specific product is safe and effective for a specific use, and that no one outside the company has verified what is actually in the vial, whether it is sterile, or whether the dose is consistent from batch to batch. Approval is the process that produces those answers. Without it, you are relying on the seller's word.

It also means the usual consumer backstops are missing. There is no approved label, no required adverse-event reporting to a public database in the way approved drugs have, and no recall infrastructure tied to a marketing authorization.

The safety notification, and what prompted it

In December 2019, the FDA and the Centers for Disease Control and Prevention issued a public safety notification after multiple patients in Nebraska were hospitalized with serious adverse events — including bacterial infections — following treatment with an unapproved product marketed as containing exosomes (FDA).

That is the core of the concern. These are biologic products derived from human tissue, often prepared in facilities that have not been inspected against the standards required for injectable biologics. A contaminated batch injected into a joint or infused intravenously is not a minor complication.

The FDA has also warned that some clinics use unproven regenerative products in ways that carry risks including infection, immune reaction, injection-site problems, and — in the case of products administered into the eye or the bloodstream — vision loss and blood clots (FDA consumer alert on regenerative medicine products, including stem cells and exosomes).

Enforcement since then

The FDA has continued to send warning and untitled letters to manufacturers and distributors of exosome products, typically citing marketing of an unapproved biologic and, in some cases, manufacturing violations. During the early COVID-19 pandemic, the FDA and Federal Trade Commission also acted against sellers promoting exosome infusions as a treatment or preventive for the virus — claims with no supporting evidence at all.

The agency's broader position on unapproved regenerative products is summarized in its patient-facing guidance (FDA: important patient and consumer information about regenerative medicine therapies).

Enforcement has been uneven, and the practical result is that products remain widely available in clinics. Availability is not authorization.

What the human evidence looks like

Thin.

The preclinical literature — cell culture and animal models — is substantial and in places encouraging, particularly for wound healing and cartilage. The human clinical literature is mostly small case series, uncontrolled reports, and industry-adjacent studies, with heterogeneous products that cannot be compared to one another. Two vials labeled "exosomes" from different suppliers may differ enormously in vesicle count, purity, cell source, and what else is in the preparation. There is no standardized potency measure.

For the most commonly marketed cosmetic uses — hair density, skin texture, post-procedure recovery — there are published reports suggesting improvement, but almost none with the randomization, blinding, and control arms needed to separate the product from the procedure. Microneedling alone improves skin. Injecting fluid into a scalp alongside other treatments confounds attribution.

If you want to see where legitimate development stands, you can search registered trials at ClinicalTrials.gov. A serious program will have a registered study with a protocol; a clinic offering the treatment for cash will usually not.

This is a meaningfully weaker evidence base than PRP, which — while itself mixed and inconsistently standardized — has multiple randomized controlled trials and systematic reviews behind it in several indications.

Cost

Exosome treatments are not covered by insurance. Advertised prices generally run from roughly $1,000 to $3,000 per session for facial or scalp applications, and can reach $3,000 to $6,000 or more for joint injections or intravenous infusions, with multi-session packages pushing totals higher. Prices vary by region, product volume, and whether the exosomes are combined with another procedure.

You are paying premium prices for a product with less human evidence behind it than cheaper alternatives.

Questions worth asking before you consent

  • What is the source material, and who manufactures it? Ask for the name.
  • Is this product the subject of an active investigational new drug application with the FDA? If the answer is vague, treat that as a no.
  • How is sterility tested, and by whom?
  • What is the specific evidence for this use — in humans, with a control group?
  • What happens if I have an adverse reaction, and who reports it?
  • Would PRP or an established treatment be a reasonable option here, and why is this better?

A clinician who cannot answer the first three is not in a position to obtain informed consent for an injectable biologic.

The honest bottom line

Exosomes may well become an important therapeutic class. The biology is plausible and the research is real. But "promising research field" and "product you should pay several thousand dollars for today" are different claims, and the gap between them is exactly what FDA approval exists to close.

Right now, no exosome product has crossed it, and the FDA has warned patients about the ones being sold. Some people will decide the potential upside is worth it anyway. That is a legitimate personal choice — but it should be made knowing that you are the trial, and no one is collecting the data.

This guide is information, not medical advice. Discuss any treatment decision with a qualified clinician who knows your history.